Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

Phase 1 Completed 40 enrolled Mateon Therapeutics Cancer Research UK · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to establish the Maximum Tolerated Dose (MTD) of OXi4503 given by weekly infusions to patients with advanced solid tumors.

Timeline

Start: 2005-07
Primary completion: 2010-09
Completion: —

Publications

Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18(5):1415-25. doi: 10.1158/1078-0432.CCR-11-2414. Epub 2012 Jan 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OXi4503	Other / unclassified	0.06 mg/m2	Intravenous

Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications